arrow
A

Adham Jurdi

natera
H指数:12
被引数:769

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial

新辅助botensilimab联合或不联合balstilimab治疗pMMR和dMMR结肠癌: UNICORN 2期试验

2026-11-020
OAAI
Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial

ctDNA阳性的结直肠癌患者术后辅助化疗: 一项随机3期试验

2026-06-080
OAAI
Tumor-informed circulating tumor DNA stratifies recurrence risk and survival in anal squamous cell carcinoma

肿瘤信息指导的循环肿瘤DNA对肛管鳞状细胞癌的复发风险和生存期进行分层。

2026-02-260
OAAI
Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Therapy

循环肿瘤DNA在评估接受新辅助治疗的局部晚期直肠癌患者肿瘤反应中的价值

Cancers
IF4.4
2026-02-110
OAAI
Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers

错配修复功能 proficient 结直肠癌的新辅助免疫疗法

Nature
IF48.5
2025-10-200
PRE
Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery: A Prospective Cohort Study

分子残留病灶及复发在行术前手术的直肠癌患者中的研究:一项前瞻性队列研究

2025-09-260
OAAI
Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study

局部晚期可切除胃或胃食管结合部腺癌治疗期间纵向循环肿瘤DNA分析:PLAGAST前瞻性生物标志物研究

2025-07-240
OAAI
ctDNA-based molecular residual disease and survival in resectable colorectal cancer

可切除结直肠癌中基于ctDNA的分子残留疾病和生存

2024-09-161
OAAI
Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
2024-03-061
OAAI
A phase II study of peri-operative modified FOLFIRINOX in localized pancreatic ductal adenocarcinoma ( PDAC)
2024-01-160
PRE
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

新辅助阿特珠单抗联合化疗治疗胃和胃食管交界处腺癌: 2期熊猫试验

2024-01-0830
OAAI
Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: GALAXY study in the CIRCULATE-Japan
2023-11-010
OA
Circulating tumor (ct)DNA as a prognostic biomarker in patients (pts) with resected colorectal cancer (CRC): An updated 24 months (mos) disease free survival (DFS) analysis from GALAXY study (CIRCULATE-Japan)
2023-10-010
OA